Thomas Chaisson, MD
General Practice · Thibodaux, LANPI 1902895279
Payments from drug & device makers
Across 175 payments — averaging $16.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$513
- Novo Nordisk$273
- GSK$213
- Lilly USA, LLC$192
- Amgen$146
- Pfizer$125
- plus $1K from 34 others
What the payments were for
- Food & beverage$2,942100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 29 | $513 |
| Novo Nordisk | 18 | $273 |
| GSK | 12 | $213 |
| Lilly USA, LLC | 11 | $192 |
| Amgen | 9 | $146 |
| Pfizer | 7 | $125 |
| Merck | 8 | $122 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $94 |
| AstraZeneca | 6 | $88 |
| Abbott | 5 | $82 |
| Sanofi-aventis U.S. LLC | 6 | $77 |
| Boehringer Ingelheim | 5 | $70 |
| Exact Sciences | 3 | $69 |
| Ironshore Pharmaceuticals Inc. | 3 | $65 |
| Corium, LLC | 3 | $63 |
| Esperion Therapeutics, Inc. | 4 | $60 |
| Novartis | 4 | $60 |
| Dexcom, Inc. | 2 | $54 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $51 |
| Sumitomo Pharma America, Inc. | 3 | $49 |
| Johnson & Johnson | 3 | $47 |
| Eisai Inc. | 3 | $47 |
| Adlon Therapeutics L.p. | 2 | $39 |
| Seqirus USA Inc | 2 | $37 |
| Astellas Pharma US Inc | 2 | $28 |
| Vanda Pharmaceuticals Inc. | 1 | $28 |
| Bayer | 2 | $28 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Phathom Pharmaceuticals, Inc. | 1 | $20 |
| Sanofi Pasteur Inc. | 1 | $19 |
| Phadia US Inc. | 1 | $19 |
| Cranial Technologies, Inc | 1 | $18 |
| Tris Pharma Inc | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $17 |
| Clarus Therapeutics Inc. | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Ironwood Pharmaceuticals, Inc | 1 | $15 |
| Shield Therapeutics Inc | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$2,942 in reported general payments places this provider in the 95th percentile of 1,221 general practice providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 91 | $103,897 |
| MounjaroTirzepatide | 65 | $85,771 |
| EliquisApixaban | 145 | $75,860 |
| JardianceEmpagliflozin | 67 | $62,120 |
| JanuviaSitagliptin Phosphate | 45 | $34,129 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 35 | $30,437 |
| TrulicityDulaglutide | 24 | $24,601 |
| EntrestoSacubitril/Valsartan | 12 | $14,152 |
| TopamaxTopiramate | 11 | $11,322 |
| TradjentaLinagliptin | 17 | $10,686 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $8,614 |
| Levothyroxine Sodium | 1,040 | $8,596 |
| FarxigaDapagliflozin Propanediol | 13 | $8,551 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $8,163 |
| KeppraLevetiracetam | 12 | $8,109 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $192 | $110,37289 claims |
| Novo NordiskOzempic | $273 | $103,89791 claims |
| PfizerEliquis | $125 | $75,860145 claims |
| Boehringer IngelheimJardiance, Tradjenta | $70 | $72,80684 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $213 | $39,05157 claims |
| MerckJanuvia | $122 | $34,12945 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $88 | $16,71325 claims |
| NovartisEntresto | $60 | $14,15212 claims |
| AbbVieLumigan, Synthroid, Armour Thyroid | $513 | $8,723102 claims |
| Astellas Pharma US IncMyrbetriq | $28 | $6,98416 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $49 | $6,65621 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,221 general practice providers in Louisiana.
Other general practice in Thibodaux
- Jared PalmerThibodaux$5K
- Chester BoudreauxThibodaux$3K
- William CaldwellMetairie$943K
- Russell DavisSaint Martinville$427K
- William MaloneLafayette$46K
- Charles RogersBogalusa$40K
- Muhammad AnjumShreveport$33K
- Melissa RatliffBarksdale Afb$22K
- Louis PassauerMandeville$20K
- Stan Cowley JrMetairie$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.